

Page 1 of 2

[X] Original [] Supplemental

Atty.Docket: REISNER = 5

## Combined Declaration for Patent Application and Power of Attorney

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN

the specification of which (check one)
[] is attached hereto; [] was filed in the United States under 35 U.S.C. §1.11 on, as  USSN*; or  [XX] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/IL97/00184; filed 10 June 1997  entry requested on*; national stage application received  USSN*; §371/§102(e) date* (*if known), and was amended on*; §371/§102(e) date* (if applicable).
and was amended on 25 June 1998 (include dates of amendments under PCT Art. 19 and 34 ty PCT).
I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office PTO) all information known by me to be material to patentability as defined in 37 C.F.R. § 1.56.  I hereby claim foreign priority benefits under 35 U.S.C. §§ 119, 365 of any prior foreign
I hereby claim foreign priority benefits under 35 U.S.C. §§ 119, 365 of any prior locegal application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:
118625   Israel   25 June 1998   IX)   I
I hereby claim the benefit under 35 U.S.C. § 120 of any prior U.S. non-provisional Application(s) or prior PCT Application(s) designating the U.S. listed below, or under § 119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:
(Application Serial No.) (Day Month Year Filed) (Status: patented, pending, abandoned)
(Application Serial No.) (Day Month Year Filed) (Status: patented, pending, abandoned)
(Application Serial No.) (Day Month Year Filed) (Status: patented, pending, abandoned)
I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.  SHERIDAN METHARK, REG. NO. 20,520 - ROCER L. BRONDY, REG. NO. 25,618 - ANNE N. KURNBAU, REG. NO. 25,884  NORMAN J. LATKER, REG. NO. 19,963 - IVER P. COOPER, REG. NO. 28,005 - ALLEN C. YUN, REG. NO. 37,971  NICK S. BRONER, REG. NO. 33,478 - Patent Agent
ADDRESS ALL CORRESPONDENCE TO BROWDY AND NEIMARK, P.L.L.C. 419-Seventh Street, N.W. Washington, D.C. 20004

The undersigned hereby authorizes the U.S. Attorneys or Agents named herein to accept and follow instructions from XTL BIOPHARMACEUTICALS LIMITED as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorney or Agent and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents named herein will be so notified by the undersigned.

-19 U

٤g

##" #

٤٤

ĨŲ

14



TO

Page <u>2</u> of <u>2</u>	Any.Docket: REISNER=5	
Title: U.S. Application filed PCT Application filed	, Serial No. PCT/IL97/00184	

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR'S SIGNATURE PULL NAME OF FIRST INVENTOR Yair REISNER itizen**s**ati RESIDENCE Old Jaffa, Israel POST OFFICE ADDRESS Mazal Kashat 4, 68037 Old Jaffa, Israel DATE FULL NAME OF SECOND JOINT INVENTOR INVENTOR Nor1698 Shlomo DAGAN CITIZENSHI RESIDENCE Israel Rehovot, Israel POST OFFICE ADDRESS Bustenai 12, 76289 Rehovot, Israel DATE FULL NAME OF THIRD JOINT INVENTOR INVENTOR' CITIZENSHIP RESIDENCE POST OFFICE ADDRESS DATE INVENTOR'S SIGNATURE FULL NAME OF FOURTH JOINT INVENTOR CITIZENSHIP RESIDENCE POST OFFICE ADDRESS INVENTOR'S SIGNATURE DATE FULL NAME OF FIFTH JOINT INVENTOR CITIZENSHIP RESIDENCE POST OFFICE ADDRESS DATE INVENTOR'S SIGNATURE FULL NAME OF SIXTH JOINT INVENTOR CITIZENSHIP RESIDENCE POST OFFICE ADDRESS DATE INVENTOR'S SIGNATURE FULL NAME OF SEVENTH JOINT INVENTOR CITIZENSHIP RESIDENCE POST OFFICE ADDRESS

all diventors must review application and declaration before signing. All alterations must be detialed and dated by all diventors prior to execution, no Alterations can be made after the declaration is signed. All proces of declaration must be seen by all inventors,

	"Card" (apr 15,) 15	::
	į	11
1	ř	
	Ę	7
	Ŧ	_
	Ļ	
diff.	3	9
27.00	= :	:
≊	:	
5	:	Ē
7	11	į
Ļ		į
į	17 11	
ģ	=	H 11 H 11
	=	

	Applicant or Patentee: Yair REISNER et al. Attorney's Docket No.: REISNER=5				
	Apoln, or Patent No.: Filed or Issued:				
	FOR: HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN				
	VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL BUSINESS ENTITY STATUS  (37 CFR 1.9(f) and 1.27(C)) - SMALL BUSINESS CONCERN				
i hereby declare that I am					
	[ ] the owner of the small business concern identified below: [XX] an official of the small business concern empowered to act on behalf of the concern identified below:				
	NAME OF SMALL BUSINESS CONCERN YEDA RESEARCH AND DEVELOPMENT CO. LTD.  ADDRESS OF SMALL BUSINESS CONCERN P.O. Box 95, Rehovot 76100, Israel				
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed persons. For purposes of this statement, (1) the number of employees of the business concern is the average over previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirect one concern controls or has the power to control the other, or a third party or parties controls or has the power control both.  I hereby declare that rights under contract or law have been conveyed to and remain with the small business concidentified above with regard to the invention entitled <u>HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN</u> by inventors <u>Yair REISNER and Shlomo DAGAN</u> described in:					
					± ≠
₫ 4	ryys analisation no, filed				
-=	[ ] patent no, [saued				
4-n 4-4 4-4 4- 4-1 4-	If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofict organization under 37 CFR 1.9(e).  **Note: Separate verified statements are required from each named person, concern or organization having right to the invention averring to their status as small entities (37 CFR 1.27).				
	to the invention averting to their status as shart entities (or one its)				
	NAME XTL BIOPHARMACEUTICALS LIMITED				
	ADDRESS Kiryat Weizmann, P.O. Box 370, Rehovot 76100, Israel  [ ] INDIVIDUAL [XX] SMALL BUSINESS CONCERN [ ] NONPROFIT ORGANIZATION				
	NAMEADDRESS				
	[ ] INDIVIDUAL [ ] SMALL BUSINESS CONCERN [ ] NONPROFIT ORGANIZATION				
	I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or a maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))				
	I hereby declare that all statements made herein of my own knowledge are true and that all statements made on informati and belief are believed to be true; and further that these statements were made with the knowledge that willful fall statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of t United States Code, and that such willful false statements may Jeopardize the validity of the application, any page issuing thereon, or any patent to which this verified at the ment is directed.				
	HAME OF PERSON SIGNING PAULINA BEN-AMI TITLE OF PERSON SIGNING OTHER THAN OWNER VICE PRESIDENT				





Applicant or Patentee: Yair REISNER et al.	Attorney's Docket No.: REJSHER=5				
Appln. or Patent No.:	Filed or Issued:				
For: HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTI	GEN				
VERIFIED STATEMENT (DECLARATION) GLAIMIN (37 GFR 1.9(f) and 1.27(G)) - 9	ig small business entity status Buall business concern				
1 hereby declare that I BM					
[ ] the owner of the small business concern identified below:					
(XX) an official of the small business concern empowered to act	on behalf of the concern identified Dalow:				
	<u>.</u>				
NAME OF SMALL BUSINESS CONCERN XTL BIOPHARMACEUTICALS LIMITE ADDRESS OF SMALL BUSINESS CONCERN Kiryat Weizmann, P.O. Box 370	D. Rehovot 76100, Israel				
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.					
I hereby declare that rights under contract or law have been identified above with regard to the invention entitled HUMAN MOD by inventors Yair REISNER and Shlomo DAGAN described in:	conveyed to and remain with the small business concern NOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN				
[ ] the specification filed herewith with title listed as	above.				
[ ] the specification filed nerewith with title tisted by	. filed				
[XX] application no, issued					
[ ] patent no.					
If the rights held by the above-identified small business organization having rights in the invention is listed below* and then the inventor, who would not qualify as an independent invention, or by any concern which would not qualify as a congenization under 37 CFR 1.9(e).	no rights to the invention are nate by any person, other inventor under 37 CFR 1.9(c) if that person made the				
*Note: Separate verified statements are required from to the invention overring to their status as small ent	each nemed person, concern or organization having rights ities (37 CFR 1.27).				
NAME YEDA RESEARCH AND DEVELOPMENT CO. LTD.					
ADDRESS P.O. Box 95, Rehovot 76100, Israel					
[ ] INDIVIDUAL [XX] SMALL BUSINESS CONCERN [ ] NO	NPROFIT ORGANIZATION				
NAME					
ADDRESS					
[ ] INDIVIDUAL [ ] SMALL BUSINESS CONCERN [ ] NO	NPROFIT ORGANIZATION				
I acknowledge the duty to file, in this application or patent, entitlement to small entity status prior to paying, or at the maintenance fee due after the date on which status as a small entity.	etity is no longer appropriate. (37 CFR 1.28(b))				
I hereby declare that all statements made herein of my own knowled and belief are believed to be true; and further that these state statements and the like so made are punishable by fine or impunited States Code, and that such willful false statements may lesuing thereon, or any patent to which this verified statement	prisonment, or both, under section 1001 of fittle 18 of the separdize the validity of the application, any patent				
WAKE OF BEDSON SIGNING MIRIT LOTAN					
NAME OF PERSON STUNING	TORIN				
TITLE OF PERSON SIGNING OTHER TARK OFFICE					
ADDRESS OF PERSON SIGNING XTL BIOPHAR MACEUTIC	· · · · · · · · · · · · · · · · · · ·				
	DATE December 10 1998				
SIGNATURE / Y will lots in	<del></del>				